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Withanolides are group of pharmacologically active compounds present in most prodigal amounts in roots and leaves of Withania somnifera  (Indian ginseng), one of the most important medicinal plant of Indian systems of 
medicine. Withanolides are basically steroidal lactones (highly oxygenated C-28 phytochemicals) and similar to ginsenosides activity. Some of the withanolides have been reported to possess immunomodulatory,  anticancer & 
other activities. In the present investigation, a quantitative structure activity relationship (QSAR) model have been developed against the MCF7, MCF7/BUS, and SK-Br-3 human solid tumor breast cancer cell lines. 
Relationship correlation coefficient (r2) and cross validation correlation coefficient (r2CV) of QSAR model were 0.77 and 0.73 for MCF7, 0.91 and 0.85 for MCF7/BUS, 0.93 and 0.90 for SK-Br-3 respectively. Developed 
QSAR model was also evaluated for prediction accuracy through internal, external and randomization validation methods. QSAR results indicate that for  MCF7 cancer cell line, atom count (all atoms), and connectivity index 
(order 2, standard) descriptors correlate well with the activity. Similarly, for , SK-Br-3 cancer cell line, Connectivity Index (order 0, standard), Dipole Vector X (debye), Molar Refractivity, and Shape Index (basic kappa, order 
2) descriptors correlated well with activity. Lastly, for MCF7/BUS cancer cell line chemical 2D descriptors viz., Atom Count (all atoms),  Dielectric Energy (kcal/mole), Total Energy (Hartree),  and Heat of Formation 
(kcal/mole)  correlate well with the breast cancer activity. Moreover, on the basis of screening for oral bioavailability, in silico ADME and toxicity risk assessment, we concluded that compounds Withn_1, Withn_3, Withn_4 
and Withn_8 have  higher activity. These results can offer useful references for directing the molecular design of  lead compound  with improved activity.
Method 
Retrieval of  Crystal structures
3D crystal structure of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) protein (PDB: 
3HB5) and chemical compounds were retrieved from PDB (www.rcsb.org) and PubChem databases 
respectively.
Cleaning, Optimization & molecular docking of Withanolide analogues 
3D structure of Withanolide analogues were designed and optimized through ChemBioOffice software. 
Molecular structures of target protein 17beta-HSD1 and chemical molecules were prepared and docked 
through Scigress Explorer v7.7 (Fujitsu). Molecular docking was performed to find out the binding 
affinity or molecular interaction energy (kcal/mol) of docked compounds calculated by using PMF 
scoring scheme. Lowest energy of docked molecule indicates high binding affinity with the target 
protein. Binding pocket of docked Withanolide analogues were studied for selection radius 3Å.
Multiple linear regression QSAR modeling for anticancer activity targeting 17beta-HSD1
Calculation of 2D and 3D molecular chemical descriptors for QSAR modeling by using forward 
stepwise multiple linear regression method and drug likeness study (Lipinski et. al., 2001) was done 
through Scigress Explorer v7.7. The model was constructed with 22 compounds in the training set, which 
was validated by the remaining molecules in the test set. We employed ‘leave-one-out’ cross validation 
procedure.
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Conclusion
• The docking results of 10 Withanolide analogues  showed that the active residues of 17beta-HSD1 
binding pocket are hydrophilic and polar in nature. 
• There was a significant correlation between binding affinity (docking energy) and the experimental  
(growth inhibition) GI50. 
• Moreover, Ale-191, Phe-192, Met-193 & Gly-198  are the key residues in the binding pockets 
responsible for molecular binding with Withanolide analogues /derivatives. 
• QSAR model for Withanolide analogs  against anticancer activity was successfully developed to 
understand the pharmacophoric factors governing its activity. Results indicate that developed QSAR 
model is robust and have good predictive accuracy for anticancer activity targeting MCF7,  SK-Br-3 and 
MCF7/BUS breast cancer cell lines.
Results
• MLR method was employed to generate a linear relationship that correlates changes in the computed 
steric and electrostatic potential fields with changes in the corresponding experimental values of the 
training compounds activity (GI50). 
• Docking results showed that all the active Withanolide analogues docked on 17beta-HSD1 with high 
binding affinity.
• 2D contour maps of Withanolide analogues were compared with the crystal structure of 17beta-HSD1 
complex (PDB: 3HB5).
• Docking results of Withanolide analogues  showed that the important residues of 17beta-HSD1 active 
pocket are hydrophilic and polar.  Ale-191, Phe-192, Met-193, & Gly-198 are the key residues in the 
binding pockets responsible for molecular binding with Withanolide analogues .
• QSAR results indicate that for  MCF7 cancer cell line, atom count (all atoms), and connectivity index 
(order 2, standard) descriptors correlate well with the activity. Similarly, for , SK-Br-3 cancer cell line, 
Connectivity Index (order 0, standard), Dipole Vector X (debye), Molar Refractivity, and Shape Index 
(basic kappa, order 2) descriptors correlated well with activity. Lastly, for MCF7/BUS cancer cell line 
chemical 2D descriptors viz., Atom Count (all atoms),  Dielectric Energy (kcal/mole), Total Energy 
(Hartree),  and Heat of Formation (kcal/mole)  correlate well with the breast cancer activity .
Figure 1. Multiple linear regression curve plot for MCF7 breast cancer cell line showing comparison of experimented 
log GI50 and predicted log GI50 (µM) (Growth inhibition). 
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Descriptors:             
                
Withn_1 Withn_2 Withn_3 Withn_4 Withn_5 Withn_6 Withn_7 Withn_8 Withn_9 Withn_10 Stand. Range
log S  for   aqueous 
solubility
-4.824 -4.670 -4.989 -4.684 -5.487 -5.377 -5.032 -5.228 -5.140 -5.220 (-6.5 / 0.5) 
log Khsa Serum 
Protein Binding
-0.095 0.337 0.226 -0.063 0.457 -5.561 0.322 0.534 0.406 0.407 (-1.5 / 1.5) 
log BB for 
brain/blood 
-2.904 -1.120 -1.469 -2.052 -1.775 -0.948 -1.409 -0.938 -0.972 -1.511 (-3.0 / 1.2) 
No. of Primary 
Metabolites
5 4 5 4 6 6 4 6 5 5 (1.0 / 8.0) 
Predicted CNS 
Activity   
-2 -2 -2 -2 -2 -1 -2 -1 -1 -2 –2 (inactive),
+2 (active)
Log IC50 for 
HERG K+ 
Channel Blockage
-2.754 -4.309 -4.483 -2.673 -4.629 -4.343 -- -4.155 -4.311 -4.558 (concern 
below -5)
Apparent Caco-2 
Permeability 
(nm/sec)  
3 351 261 17 164 491 211 475 464 199 (<25 poor, 
>500 great)
Apparent MDCK   
Permeability 
(nm/sec)    
1 159 116 8 74 229 92 221 216 86 (<25 poor, 
>500 great)
log Kp for skin 
permeability
-6.218 -3.493 -3.767 -4.880 -4.063 -3.392 -4.010 -3.464 -3.463 -3.983 (–8.0 to –1.0, 
Kp in cm/hr)
Jm, max 
transdermal 
transport rate 
0.000 0.003 0.0001 0.000 0.000 0.001 0.000 0.001 0.001 0.000 (micrograms/c
m^2-hr)
Lipinski Rule of 5 
Violations
1 0 1 1 1 0 0 0 0 0 maximum is 4
Jorgensen Rule of 
3 Violations     
1 0 0 1 0 0 0 0 0 0 (maximum is 
3)
% Human Oral 
Absorption in GI 
(+-20%)   
37 91 73 53 73 95 86 95 93 86 (<25% is 
poor)
Qual. Model for 
Human Oral 
Absorption
Medium HIGH HIGH Medium Medium HIGH HIGH HIGH HIGH HIGH (>80% is 
high)
Table 1. Compliance of Withanolide analogues to computational parameters of 
pharmacokinetics (ADME).
Introduction
QSAR model for MCF7 breast cancer cell line :
Predicted log GI50(µM) = 0.230892 x Atom Count (all atoms)
 -0.297816 x Connectivity Index (order 2, standard)
 -0.0275772 x Molecular Weight 
+2.92179 
[r2CV=0.733719 r2=0.771875]
Figure 2. Multiple linear regression curve plot for SK-Br-3 breast cancer cell line showing comparison of experimented 
log GI50 and predicted log GI50 (µM) (Growth inhibition). 
QSAR model for  SK-Br-3   breast cancer cell line:
Predicted log GI50 (µM) = -0.847554 x Connectivity Index 
 -0.105787 x Dipole Vector X (debye)
 +0.247149 x Molar Refractivity  
 -1.1174 x Shape Index (basic kappa, order 2)
 -2.22636
 [r2CV=0.903815 r2=0.934013]
Figure 3. Multiple linear regression curve plot for MCF7/BUS  breast cancer cell line showing comparison of 
experimented log GI50 and predicted log GI50 (µM)  (Growth inhibition).
QSAR model for MCF7 / BUS breast cancer cell line:
Predicted log GI50 (µM) = 0.23502 x Atom Count (all atoms)
 +1.84326 x Dielectric Energy (kcal/mole)
 +0.0797426 x Total Energy (Hartree) 
 -0.00518695 x Heat of Formation (kcal/mole)
 +5.58755
 [r2CV =0.856145 r2=0.914576 
Table 2. Compliance of active Withanolide analogues against  in silico toxicity risk 
parameters
Figure 5. Docking score of  Withanolide analogues against  
human anticancer target 17beta-HSD1
Figure  4. Superimposition of Withanolides 
analogues and  E2B showing  complementary 
structural conformation.
Withn_10 docked on 17beta-HSD1  anticancer 
receptor with docking score -27.682 kcal/mol.  
Withn_9 docked on 17beta-HSD1  anticancer 
receptor with docking score -34.901 kcal/mol.
Figure 6. Molecular insight of  Withanolide analogues  docked on human anticancer target 17beta-HSD1 showing 
conserved pocket residues of binding site.
Withn_7 docked on 17beta-HSD1  anticancer 
receptor with docking score -31.161 kcal/mol.
Withn_6 docked on 17beta-HSD1  anticancer 
receptor with docking score -17.647 kcal/mol.
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